文献速递血栓与止血

高血浆C1抑制剂水平与未来静脉血栓栓塞风险降低相关

High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2023-03-31

基于特罗姆瑟研究的巢式病例对照研究纳入405例静脉血栓栓塞患者和829名年龄性别匹配对照,发现血浆C1抑制剂最高四分位组较低四分位组静脉血栓栓塞风险降低(OR 0.68,95%CI 0.49-0.96),深静脉血栓OR 0.60(95%CI 0.39-0.89),肺栓塞OR 0.85(95%CI 0.52-1.38),体外实验显示C1抑制剂抑制内源性凝血途径触发的凝血酶生成。

要点

  • 血浆C1抑制剂最高四分位组静脉血栓栓塞风险较低四分位组降低,OR 0.68(95%CI 0.49-0.96)。
  • 深静脉血栓亚组OR 0.60(95%CI 0.39-0.89),肺栓塞亚组OR 0.85(95%CI 0.52-1.38)。
  • 体外实验显示外源性C1抑制剂减少内源性凝血途径激活剂触发的凝血酶生成,对外源性途径激活剂触发者无此效应。

核心结论

  • 高血浆C1抑制剂水平与静脉血栓栓塞风险降低相关,且C1抑制剂在体外抑制内源性凝血途径启动的凝血酶生成。

研究设计与样本

  • 巢式病例对照研究,纳入405例静脉血栓栓塞患者和829名年龄性别匹配对照,样本源自特罗姆瑟研究。
  • 采用全外显子组测序数据进行定量性状位点分析探索C1抑制剂的遗传调控。
  • 通过校准自动血栓造影术在体外评估血浆C1抑制剂水平对凝血的影响。

主要发现

  • 血浆C1抑制剂最高四分位组较低四分位组静脉血栓栓塞风险降低,OR 0.68(95%CI 0.49-0.96)。
  • 亚组分析中,深静脉血栓对应的OR为0.60(95%CI 0.39-0.89),肺栓塞对应的OR为0.85(95%CI 0.52-1.38)。
  • 未发现血浆C1抑制剂水平的显著遗传决定因素。
  • 向正常人血浆中加入外源性C1抑制剂可减少内源性凝血途径激活剂触发的凝血酶生成,但对外源性凝血途径激活剂触发的凝血酶生成无此效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: C1-inhibitor (C1INH) is a broad-acting serine protease inhibitor with anticoagulant activity. The impact of C1INH plasma levels within the normal physiological range on risk of venous thromboembolism (VTE) is unknown. We assessed the association of plasma C1INH levels and VTE risk and evaluated the impact of C1INH on thrombin and plasmin generation in ex vivo assays. METHODS: A nested case-control study with 405 patients with VTE and 829 age- and sex-matched controls was derived from the Tromsø Study. Odds ratios (ORs) with 95% confidence intervals (95% CI) for VTE were estimated across plasma C1INH quartiles. Genetic regulation of C1INH was explored using quantitative trait loci analysis of whole exome sequencing data. The effect of plasma C1INH levels on coagulation was evaluated ex vivo by calibrated automated thrombography. RESULTS: Individuals with C1INH levels in the highest quartile had a lower risk of VTE (OR 0.68, 95% CI: 0.49-0.96) compared with those with C1INH in the lowest quartile. In subgroup analysis, the corresponding ORs were 0.60 (95% CI: 0.39-0.89) for deep vein thrombosis and 0.85 (95% CI: 0.52-1.38) for pulmonary embolism, respectively. No significant genetic determinants of plasma C1INH levels were identified. Addition of exogenous C1INH to normal human plasma reduced thrombin generation triggered by an activator of the intrinsic coagulation pathway, but not when triggered by an activator of the extrinsic coagulation pathway. CONCLUSIONS: High plasma levels of C1INH were associated with lower risk of VTE, and C1INH inhibited thrombin generation initiated by the intrinsic coagulation pathway ex vivo.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Grover SP, Snir O, Hindberg K, et al. High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism. J Thromb Haemost. 2023. PMID: 37003465. doi:10.1016/j.jtha.2023.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。